Ceramides, P CERAM

Synonyms
Allscripts (AEHR) Order Name	Ceramides, Plasma
Sunrise Clinical Manager (SCM) Order Name	Ceramides, Plasma
Clinical Info	Evaluating for the risk of major adverse cardiovascular events within the next 1 to 5 years MI-Heart Ceramides is a blood test that measures risk for adverse cardiovascular events and quantifies plasma ceramides. Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque.
Specimen Type
Container	Lavender Top Tube
Collection Instructions	Collection Container/Tube: Lavender top (EDTA) Specimen : 1 mL EDTA Plasma (0.5 mL min) Transport Temperature: Frozen Collection Instructions: Freeze within 8 hours. Patient Preparation: Patients should not be receiving Intralipid because it may cause false-elevations in measured ceramides
Transport Instructions
Specimen Stability	8 Hours Room Temperature 1 Day Refrigerated 30 Days frozen
Methodology	Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Days Performed	TAT: 3-10 Days
Performing Laboratory	Mayo Clinic Laboratories
CPT	0119U LOINC Code: 93883-7
PDM	1859767
Result Interpretation MI-Heart Ceramide Risk Score: 0-2 Lower risk 3-6 Moderate risk 7-9 Increased risk 10-12 Higher risk Ceramide (16:0): 0.19-0.36 mcmol/L Ceramide (18:0): 0.05-0.14 mcmol/L Ceramide (24:1): 0.65-1.65 mcmol/L Ceramide (16:0)/(24:0): <0.11 Ceramide (18:0)/(24:0): <0.05 Ceramide (24:1)/(24:0): <0.45 Reference values have not been established for patients who are <18 years of age. Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.
Forms